Thomson Corp. has announced that it has acquired Current Drugs, Ltd., a
privately held U.K.-based provider of integrated competitor intelligence
services to the research solutions market. Thomson also announced
the acquisition of Lawtel, a U.K.-based legal online information
Current Drugs, Ltd.
Current Drugs provides databases, systems, and services such
as the Investigational Drugs database (IDdb), a resource for scientists
and business executives involved in drug research and development.
Financial terms of the agreement were not disclosed.
According to the announcement, the addition of Current Drugs
enhances the offerings that Thomson provides to the drug discovery
and development functions within pharmaceutical and biotechnology
companies. When combined with otherThomson products and businesses
such as Derwent World Patent Index, Derwent GENESEQ, and ISI Web
of Science, as well as the work-flow capabilities ofWila Verlag,
Current Drugs further enables Thomson to deliver a highly differentiated,
comprehensive research solution to the pharmaceutical and biotechnology
"This is a very exciting development for all involved," said
Mike Tansey, CEO ofThomson Scientific. "Thomson brings to Current
Drugs the additional expertise, must-have content, and infrastructure
needed to grow the business and meet the expanding needs of its
customers. And with the addition of this business, Thomson will
soon be able to offer a range of databases and services on the
IDdb platform that will help customers achieve improved productivity
in their R&D organizations."
Current Drugs' IDdb delivers content in a manner that enables
integration with a client's own proprietary data and supports
the researcher work flow by using a proprietary thesaurus. Current
Drugs also provides products that focus on specific areas of scientific
research, including the review journal Current Opinion in Drug
Discovery and Development and patent-based competitor intelligence
services for the bio-pharmaceutical sector.
Lawtel will be managed by Sweet & Maxwell, a Thomson business
and a leading legal publisher in the U.K. and Ireland. Terms of
the agreement were not disclosed.
Lawtel offers current awareness and other legal services that
are designed to allow lawyers to keep in touch with the latest
legal developments. The service complements Sweet & Maxwell's
existing family of online products, particularly Westlaw U.K.,
a premium legal research tool. According to the announcement,
Lawtel's deep penetration in key market segments, including small
law firms, the bar, and in-house counsel, strengthens Sweet &
Maxwell's ability to reach a broader range of legal customers.
Brian H. Hall, Thomson Legal & Regulatory president and
CEO, said: "At Thomson Legal & Regulatory, we are continually
investing in our global portfolio of online products. The Lawtel
acquisition will help us reach a larger spectrum of legal and
regulatory professionals and ensure our customers keep their competitive
edge by having access to information of unparalleled breadth and
Mike Boswood, managing director of Thomson Legal & Regulatory
Europe, said: "This move supports our long-term strategy of delivering
superior, value-added content in a format that lets customers
make better decisions faster. Our customers will now have access
to the best of both content worlds: current awareness and primary
law content. We are excited about the opportunities ahead for
us and pledge to make Lawtel an even stronger service."
Source: Thomson Corp., Toronto, 416/360-8700; http://www.thomson.com.